Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain Metastases

NCT06163820 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Melanoma Brain Metastases

Interventions

DRUG: Bevacizumab
DRUG: Ipilimumab
DRUG: Nivolumab
RADIATION: Hypofractionated stereotactic radiotherapy

Sponsor

Melanoma and Skin Cancer Trials Limited